Real-World Impact of an In-House Dihydropyrimidine Dehydrogenase (DPYD) Genotype Test on Fluoropyrimidine Dosing, Toxicities, and Hospitalizations at a …
DG Nguyen, SA Morris, A Hamilton… - JCO Precision …, 2024 - ascopubs.org
PURPOSE Fluoropyrimidine-related toxicity and mortality risk increases significantly in
patients carrying certain DPYD genetic variants with standard dosing. We implemented …
patients carrying certain DPYD genetic variants with standard dosing. We implemented …
Implementation of upfront DPYD genotyping with a low-cost and high-throughput assay to guide fluoropyrimidine treatment in cancer patients
M Pinheiro, A Peixoto, P Rocha, C Santos… - Pharmacogenetics …, 2023 - journals.lww.com
Objectives Genetic variants in the dihydropyrimidine dehydrogenase (DPYD) gene are
associated with reduced dihydropyrimidine dehydrogenase enzyme activity and can cause …
associated with reduced dihydropyrimidine dehydrogenase enzyme activity and can cause …
Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis
MJ Deenen, D Meulendijks, A Cats… - Journal of Clinical …, 2016 - ascopubs.org
Purpose Fluoropyrimidines are frequently prescribed anticancer drugs. A polymorphism in
the fluoropyrimidine metabolizing enzyme dihydropyrimidine dehydrogenase (DPD; ie …
the fluoropyrimidine metabolizing enzyme dihydropyrimidine dehydrogenase (DPD; ie …
Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse events
TJ Wigle, BL Povitz, S Medwid, WA Teft… - Clinical and …, 2021 - Wiley Online Library
Consensus guidelines exist for genotype‐guided fluoropyrimidine dosing based on variation
in the gene dihydropyrimidine dehydrogenase (DPYD). However, these guidelines have not …
in the gene dihydropyrimidine dehydrogenase (DPYD). However, these guidelines have not …
Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia
A Wu, H Anderson, C Hughesman, S Young… - Frontiers in …, 2023 - frontiersin.org
Background: Fluoropyrimidine toxicity is often due to variations in the gene (DPYD)
encoding dihydropyrimidine dehydrogenase (DPD). DPYD genotyping can be used to …
encoding dihydropyrimidine dehydrogenase (DPD). DPYD genotyping can be used to …
Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased …
CW Ockeloen, A Raaijmakers… - Journal of Oncology …, 2023 - journals.sagepub.com
Decreased dihydropyrimidine dehydrogenase enzyme activity is associated with severe
fluoropyrimidine-associated toxicity. Four clinically relevant variants in the DPYD gene are …
fluoropyrimidine-associated toxicity. Four clinically relevant variants in the DPYD gene are …
Fluoropyrimidine-associated toxicity and DPYD variants c. 85T> C, c. 496A> G, and c. 1236G> A: impact of haplotype
S Medwid, TJ Wigle, RB Kim - Cancer Chemotherapy and Pharmacology, 2023 - Springer
Dihydropyrimidine dehydrogenase (DPYD) is the rate-limiting step in fluoropyrimidines
metabolism. Currently, genotype-guided fluoropyrimidine dosing is recommended for four …
metabolism. Currently, genotype-guided fluoropyrimidine dosing is recommended for four …
Developing DPYD Genotyping Method for Personalized Fluoropyrimidines Therapy
BYL Wong, Z Li, MJ Raphael… - The Journal of …, 2024 - academic.oup.com
Background Fluoropyrimidine drugs are widely used in chemotherapy to treat solid tumors.
However, severe toxicity has been reported in 10% to 40% of patients. The DPYD gene …
However, severe toxicity has been reported in 10% to 40% of patients. The DPYD gene …
[HTML][HTML] Dihydropyrimidine dehydrogenase (DPD) polymorphisms knocking on the door
MDS Donadio, DM Carraro, GT Torrezan… - …, 2022 - ncbi.nlm.nih.gov
Identifying polymorphisms in the dihydropyrimidine dehydrogenase (DPYD) genes is
gaining importance as predictors of fluoropyrimidine-associated toxicity. The …
gaining importance as predictors of fluoropyrimidine-associated toxicity. The …
Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary …
DK Lau, C Fong, F Arouri, L Cortez, H Katifi… - BMC cancer, 2023 - Springer
Background Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolism of
fluoropyrimidines. Variations in the encoding DPYD gene are associated with severe …
fluoropyrimidines. Variations in the encoding DPYD gene are associated with severe …